Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair

Last updated: November 7, 2024
Sponsor: Mayo Clinic
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Heartburn

Hernia

Treatment

LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION

Clinical Study ID

NCT04795934
19-005226
  • Ages 22-80
  • All Genders

Study Summary

This single-blind randomized control study will follow 142 subjects across 7 sites randomized on a 1:1 ratio to compare treatment efficacy and safety between TIF and LNF in GERD patients with hiatal hernia undergoing hernia repair.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 22-80 years of age

  2. Subjects have GERD with hiatal hernia < 5 cm (defined as maximum ,axial height fromend of the esophagus to diaphragm by any study including upper endoscopy esophagramand or at time of surgery) and Hill grade III or IV

  3. Pathologic reflux while off PPI based on Lyon criteria by either of the following:

3.1. Conclusive evidence for pathologic reflux defined as acid exposure time (AET) > 6% (worst day) or LA grade C or D esophagitis.

3.2. Borderline evidence of pathologic reflux defined as presence of one of thefollowing parameters: AET 4-6%, LA grade A or B.

  1. Commitment to long-term study

  2. Ability to give consent individually or by a legally authorized representative

Exclusion

Exclusion Criteria:

  1. Hiatal hernia > 5 cm (defined as maximum axial height from end of the esophagus todiaphragm by any study including upper endoscopy esophagram and or at time ofsurgery)

  2. Evidence of clinically significant major esophageal motility disorder as determinedby the site primary investigator

  3. Pregnancy (in females) at time of procedure

  4. Previous anti-reflux procedure

  5. Subjects requiring mesh treatment at time of procedure

  6. At the discretion of the site PI for subject safety

  7. BMI > 35 at time of surgery.

  8. Prior gastric surgery that may affect ability to perform either procedure or affectnormal gastric function (e.g. gastrectomy, gastric bypass, sleeve gastrectomy,pyloroplasty.

  9. Severe gastroparesis

Study Design

Total Participants: 142
Treatment Group(s): 1
Primary Treatment: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION
Phase:
Study Start date:
January 26, 2021
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • University of California Irvine

    Irvine, California 92697
    United States

    Site Not Available

  • University of Southern California

    Los Angeles, California 90033
    United States

    Site Not Available

  • Institute of Esophageal and Reflux Surgery

    Englewood, Colorado 880113
    United States

    Site Not Available

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • The University of Texas at Austin

    Austin, Texas 78712
    United States

    Site Not Available

  • University of Texas Health Science Center at Houston

    Houston, Texas 77030
    United States

    Site Not Available

  • Fox Valley Surgical

    Appleton, Wisconsin 54911
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.